A trade-off for the unprecedented speed with which the US Food and Drug Administration is assessing the coronavirus vaccines is evident in the briefing document for the upcoming advisory committee meeting on Moderna, Inc.’s candidate.
Moderna transmitted additional efficacy and safety data to the agency on 4 and 7 December, respectively, a few days after...







